Active pharmaceutical ingredient (API) manufacturer Divi’s Laboratories reported consolidated net profit for June quarter increased nearly 27% to ₹545 crore compared with ₹430 crore a year earlier.
The net profit came on an almost 14% increase in the revenue from operations to ₹2,410 crore (₹2,118 crore). Sequentially, however, both the net profit and revenue from operations declined.
The company, which specialises in generic APIs, custom synthesis and nutraceuticals, had for the March quarter posted ₹662 crore net profit and ₹2,585 crore revenue from operations. Divi’s shares on Wednesday closed 4.29% lower to ₹6,134.25 each on the BSE.
Published – August 06, 2025 10:31 pm IST
